Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Medical device momentum with near-term catalysts: stock is up about 31.6% over 21 trading days, Q2 2026 earnings are due 2026-08-06, and recent CE mark expansion plus Libre 3 Plus compatibility in Europe support growth. Fundamentals are improving with record shipments and positive quarterly free cash flow.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Improving profitability ⢠Negative cash flow ⢠Elevated leverage TNDM shows improving margins and narrower losses, but worsening cash burn and high leverage make the stock a speculative, balance-sheet-sensitive investment.
Price Behavior
Key Price Behavior Insights: ⢠Negative momentum ⢠Broken support ⢠Oversold risk Support Level: $18.80 Resistance Level: $21.40â$22.10 TNDM is bearish over the last month, down 11% and below $22.10 resistance, with $18.80 support critical despite an RSI-near-oversold rebound possibility.
Sentiment & News
Key News Insights: ⢠Narrowing losses ⢠Record shipments ⢠Growth expansion Tandem's improving profitability, record pump shipments and strategic expansion plans outweighed a modest revenue miss, driving strong investor optimism.
AI Summary
TNDM is a higher-risk turnaround where record shipments and a 57% gross margin signal credible operating leverage toward breakeven, but worsening free-cash-flow burn and $739M of debt mean investors should wait for sustained revenue acceleration and cash conversion before underwriting the recovery.
Description
Tandem Diabetes Care, Inc. develops and sells insulin delivery systems and companion software for people with insulin-dependent diabetes in the United States and abroad. Its core offering is a modular pump platform that includes the pump, disposable insulin cartridge and infusion set, with versions that integrate automated insulin-delivery algorithms and continuous glucose monitor data; the company also provides software update tools and web and mobile applications for therapy data management. Tandem maintains development and commercialization agreements with CGM manufacturers including Dexcom and Abbott, and is headquartered in San Diego, California; it was incorporated in 2006 and adopted its current name in 2008.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 3 | Aug 10 | TNDM | Tandem Diabetes Care, Inc. | Medical device momentum with near-term catalysts: stock is up about 31.6% over 21 trading days, Q2 2026 earnings are due 2026-08-06, and recent CE mark expansion plus Libre 3 Plus compatibility in Europe support growth. Fundamentals are improving with record shipments and positive quarterly free cash flow. | Closed | +13.4% |
| Jun 8 | Jun 15 | TNDM | Tandem Diabetes Care, Inc. | Medtech catalyst setup: FDA cleared Control-IQ+ for pregnancy in type 1 diabetes on 2026-04-27, CE mark expansion in Europe was announced on 2026-06-05 for pregnancy use and type 2 diabetes, Q1 showed record pump shipments/sales/gross margin, and the stock is up about 20% over 21 trading days. | Closed | -9.3% |